Takeda divests select non-core assets in Europe to Cheplapharm for approximately $562m

This article was originally published here

Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products. Takeda will receive an upfront payment of

The post Takeda divests select non-core assets in Europe to Cheplapharm for approximately $562m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply